Overcoming the diagnostic gap in mild cognitive impairment in Parkinson’s disease: a pilot study employing a machine learning-/augmented reality-based digital biomarker

At Altoida, we use digital biomarkers to radically change the method of assessing brain health and cognitive diseases. After nearly two decades of research, we are developing a platform and device to measure and analyze cognitive biomarkers associated with cognitive impairment to evaluate perceptual and memory function.